drugset / Trial / NCT04965519
A Study of RC48-ADC for the Treatment of HER2-expressing Gynecological Malignancies
NaSingle-groupOpen-labelTreatment
Summary
This study will evaluate the effectiveness and safety of intravenous injection of RC48-ADC in the treatment of HER2 expression (HER2 positive and HER2 low expression) gynecological malignancies.
Timeline
- Start
- 2021-12-21
- Primary completion
- 2024-10
- Completion
- 2025-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Disitamab Vedotin | Monoclonal antibody | 2 mg/kg | Intravenous |